|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Transplantation of collagen scaffold with autologous bone marrow mononuclear cells promotes functional endometrium reconstruction via downregulating ΔNp63 expression in Asherman's syndrome显示文摘Asherman's syndrome(AS) is a common disease that presents endometrial regeneration disorder. However, little is known about its molecular features of this aregenerative endometrium in AS and how to reconstruct the functioning endometrium for the patients with AS. Here, we report that ΔNp63 is significantly upregulated in residual epithelial cells of the impaired endometrium in AS; the upregulated-ΔNp63 induces endometrial quiescence and alteration of stemness. Importantly, we demonstrate that engrafting high density of autologous bone marrow mononuclear cells(BMNCs) loaded in collagen scaffold onto the uterine lining of patients with AS downregulates ΔNp63 expression, reverses ΔNp63-induced pathological changes, normalizes the stemness alterations and restores endometrial regeneration. Finally, five patients achieved successful pregnancies and live births. Therefore, we conclude that ΔNp63 is a crucial therapeutic target for AS. This novel treatment significantly improves the outcome for the patients with severe AS. | Guangfeng Zhao Yun Cao Xianghong Zhu Xiaoqiu Tang Lijun Ding Haixiang Sun Juan Li Xinan Li Chenyan Dai Tong Ru Hui Zhu Jingjie Lu Caimei Lin Jingmei Wang Guijun Yan Huiyan Wang Lei Wang Yimin Dai Bin Wang Ruotian Li Jianwu Dai Yan Zhou Yali Hu | 2017 | Science China(Life Sciences)2017，60，4： | 39 |
| 2 | Micro RNA in inflammatory bowel disease: Translational research and clinical implication显示文摘Idiopathic inflammatory bowel disease(IBD) predominantly includes ulcerative colitis and Crohn's disease. The pathogenesis of IBD is complex and not completely understood. Micro RNAs belong to a class of noncoding small RNAs that post-transcriptionally regulate gene expression. Unique micro RNA expression profiles have been explored in IBD. In this review,we focus on the unique micro RNA expression pattern in both tissue and peripheral blood from IBD patients and emphasize the potential diagnostic and therapeutic applications. The discovery of micro RNAs has contributed to our understanding of IBD pathogenesis and might lead to clinical advance in new therapeutics. | Kurt Fisher Jingmei Lin | 2015 | World Journal of Gastroenterology2015，21，43： | 8 |
| 3 | Comparison of nonhuman primates identified the suitable model for COVID-19显示文摘Identification of a suitable nonhuman primate(NHP)model of COVID-19 remains challenging.Here,we characterized severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)infection in three NHP species:Old World monkeys Macaca mulatta(M.mulatta)and Macaca fascicularis(M.fascicularis)and New World monkey Callithrix jacchus(C.jacchus).Infected M.mulatta and M.fascicularis showed abnormal chest radiographs,an increased body temperature and a decreased body weight.Viral genomes were detected in swab and blood samples from all animals.Viral load was detected in the pulmonary tissues of M.mulatta and M.fascicularis but not C.jacchus.Furthermore,among the three animal species,M.mulatta showed the strongest response to SARS-CoV-2,including increased inflammatory cytokine expression and pathological changes in the pulmonary tissues.Collectively,these data revealed the different susceptibilities of Old World and New World monkeys to SARS-CoV-2 and identified M.mulatta as the most suitable for modeling COVID-19. | Shuaiyao Lu Yuan Zhao Wenhai Yu Yun Yang Jiahong Gao Junbin Wang Dexuan Kuang Mengli Yang Jing Yang Chunxia Ma Jingwen Xu Xingli Qian Haiyan Li Siwen Zhao Jingmei Li Haixuan Wang Haiting Long Jingxian Zhou Fangyu Luo Kaiyun Ding Daoju Wu Yong Zhang Yinliang Dong Yuqin Liu Yinqiu Zheng Xiaochen Lin Li Jiao Huanying Zheng Qing Dai Qiangming Sun Yunzhang Hu Changwen Ke Hongqi Liu Xiaozhong Peng | 2020 | Signal Transduction and Targeted Therapy2020，5，1： | 5 |
| 4 | Outcomes of submucosal(T1b) esophageal adenocarcinomas removed by endoscopic mucosal resection显示文摘AIM To investigate the outcomes and recurrences of p T1 b esophageal adenocarcinoma(EAC) following endoscopic mucosal resection(EMR) and associated treatments.METHODS Patients undergoing EMR with pathologically confirmed T1 b EAC at two academic referral centers were retrospectively identified.Patients were divided into 4 groups based on treatment following EMR:Endoscopic therapy alone(group A),endoscopic therapy with either chemotherapy,radiation or both(group B),surgicalresection(group C) or no further treatment/lost to follow-up(<12 mo)(group D).Pathology specimens were reviewed by a central pathologist.Follow-up data was obtained from the academic centers,primary care physicians and/or referring physicians.Univariate analysis was performed to identify factors predicting recurrence of EAC.RESULTS Fifty-three patients with T1 b EAC underwent EMR,of which 32(60%) had adequate follow-up ≥ 12 mo(median 34 mo,range 12-103).There were 16 patients in group A,9 in group B,7 in group C and 21 in group D.Median follow-up in groups A to C was 34 mo(range 12-103).Recurrent EAC developed overall in 9 patients(28%) including 6(38%) in group A(median:21 mo,range:6-73),1(11%) in group B(median:30 mo,range:30-30) and 2(29%) in group C(median 21 mo,range:7-35.Six of 9 recurrences were local;of the 6 recurrences,5 were treated with endoscopy alone.No predictors of recurrence of EAC were identified.CONCLUSION Endoscopic therapy of T1 b EAC may be a reasonable strategy for a subset of patients including those either refusing or medically unfit for esophagectomy. | Darren D Ballard Neel Choksi Jingmei Lin Eun-Young Choi B Joseph Elmunzer Henry Appelman Douglas K Rex Hala Fatima William Kessler John M DeWitt | 2016 | World Journal of Gastrointestinal Endoscopy2016，8，20： | 2 |
| 5 | Distinct Clinicohistologic Features of Inflammatory Bowel Disease-associated Colorectal Adenocarcinoma: In Comparison With Sporadic Microsatellite-stable and Lynch Syndrome-related Colorectal Adenocarcinoma显示文摘 | Xiuli Liu John R. Goldblum Zijin Zhao Michael Landau Brandie Heald Rish Pai Jingmei Lin | 2012 | The American Journal of Surgical Pathology2012，，8： | 2 |
| 6 | Histopathological characterization of cholecystectomy specimens in patients with inflammatory bowel disease显示文摘 | Jingmei Lin Bo Shen Hwa-Jeong Lee John R. Goldblum | 2012 | Journal of Crohn’s and Colitis2012，，9： | 1 |
| 7 | The effect of collagen-binding vascular endothelial growth factor on the remodeling of scarred rat uterus following full-thickness injury显示文摘 | Nacheng Lin Xin’an Li Tianran Song Jingmei Wang Kui Meng Jun Yang Xianglin Hou Jianwu Dai Yali Hu | 2011 | Biomaterials2011，，： | 1 |
| 8 | Substantial hepatic necrosis is prognostic in fulminant liver failure显示文摘AIM To evaluate if any association existed between the extent of hepatic necrosis in initial liver biopsies and patient survival.METHODS Thirty-seven patients with fulminant liver failure, whose liver biopsy exhibited substantial necrosis, were identified and included in the study. The histological and clinical data was then analyzed in order to assess the relationship between the extent of necrosis and patient survival, with and without liver transplantation. The patients were grouped based on the etiology of hepatic necrosis. Each of the etiology groups were then further stratified according to whether or not they had received a liver transplant post-index biopsy, and whether or not the patient survived.RESULTS The core tissue length ranged from 5 to 44 mm with an average of 23 mm. Causes of necrosis included 14 autoimmune hepatitis, 10 drug induced liver injury(DILI), 9 hepatitis virus infection, and 4 unknown origin. Among them, 11 showed submassive(26%-75% of the parenchymal volume) and 26 massive(76%-100%) necrosis. Transplant-free survival was worse in patients with a higher extent of necrosis(40%, 71.4% and 100% in groups with necrosis of 76%-100%, 51%-75%and 26%-50%, respectively). Additionally, transplantfree survival rates were 66.7%, 57.1%, and 25.0% in groups of autoimmune hepatitis, DILI, and viral hepatitis, respectively. Even after liver transplantation, the survival rate in patients as a result of viral hepatitis remained the lowest(80%, 100%, and 40% in groups of autoimmune hepatitis, DILI, and viral hepatitis, respectively).CONCLUSION Adequate liver biopsy with more than 75% necrosis is associated with significant transplant-free mortality that is critical in predicting survival. | Paul Ndekwe Marwan S Ghabril Yong Zang Steven A Mann Oscar W Cummings Jingmei Lin | 2017 | World Journal of Gastroenterology2017，23，23： | 1 |
| 9 | Differential Expression of miR-31 between Inflammatory Bowel Disease and Microscopic Colitis显示文摘 | Chen Zhang Zijin Zhao Hany Osman Rao Watson ILKe Nalbantoglu Jingmei Lin | 2014 | MicroRNA2014，，3： | 1 |
| 10 | Electrochemically Supported Deoxygenation of Epoxides into Alkenes in Aqueous Solution显示文摘 | Huang Jingmei Lin Zhiquan Chen Dongsong | 2012 | ORGANIC LETTERS2012，14，1： | 1 |
| 11 | Validation of American Joint Committee on Cancer 8th edition of TNM staging in resected distal pancreatic cancer显示文摘BACKGROUND In order to improve risk stratification and clinical management of the pancreatic ductal adenocarcinoma(PDAC),the American Joint Committee on Cancer(AJCC)has published its eighth edition staging manual.Some major changes have been introduced in the new staging system for both T and N categories.Given the rarity of resectable disease,distal pancreatic cancer is likely underrepresented in the published clinical studies,and how the impact of the staging system actually reflects on to clinical outcomes remain unclear.AIM To validate the AJCC 8th edition of TNM staging in distal PDAC.METHODS A retrospective cohort study was performed in seven academic medical centers in the United States.Clinicopathological prognostic factors associated with progression-free survival(PFS)and overall survival(OS)were evaluated through univariate and multivariate analyses.RESULTS Overall,454 patients were enrolled in the study,and were divided into 2 subgroups:Invasive intraductal papillary mucinous neoplasms(IPMN)(115 cases)and non-IPMN associated adenocarcinoma(339 cases).Compared to invasive IPMN,non-IPMN associated adenocarcinomas are more common in relatively younger patients,have larger tumor size,are more likely to have positive lymph nodes,and are associated with a higher tumor(T)stage and nodal(N)stage,lymphovascular invasion,perineural invasion,tumor recurrence,and a worse PFS and OS.The cohort was predominantly categorized as stage 3 per AJCC 7th edition staging manual,and it’s more evenly distributed based on 8th edition staging manual.T and N staging of both 7th and 8th edition sufficiently stratify PFS and OS in the entire cohort,although dividing into N1 and N2 according to the 8th edition does not show additional stratification.For PDAC arising in IPMN,T staging of the 7th edition and N1/N2 staging of the 8th edition appear to further stratify PFS and OS.For PDAC without an IPMN component,T staging from both versions fails to stratify PFS and OS.CONCLUSION The AJCC 8th edition TNM staging system provides even distribution for the T staging,however,it does not provide better risk stratification than previous staging system for distal pancreatic cancer. | Feng Yin Mohammed Saad Hao Xie Jingmei Lin Christopher R Jackson Bing Ren Cynthia Lawson Dipti M Karamchandani Belen Quereda Bernabeu Wei Jiang Teena Dhir Richard Zheng Christopher W Schultz Dongwei Zhang Courtney L Thomas Xuchen Zhang Jinping Lai Michael Schild Xuefeng Zhang Xiuli Liu | 2020 | World Journal of Gastrointestinal Pharmacology and Therapeutics2020，11，2： | 1 |
| 12 | 脾血管浸润是胰体尾癌切除术后的不良预后因素显示文摘背景:由于较高的远处转移率,胰体尾癌是致死率最高的肿瘤之一。本研究旨在评估脾血管浸润对于胰体尾癌切除术患者的预后价值。方法:在这项回顾性研究中,我们收集了454例胰体尾癌患者的临床病理资料,通过单因素和多因素分析明确本组患者无进展生存(PFS)和总体生存(OS)的预后影响因素,重点关注脾动/静脉浸润的预后价值。结果:单因素分析结果显示,肿瘤较大、非导管内乳头状黏液瘤(non-IPMN)相关的腺癌、低分化、pT3期、淋巴结转移、脉管浸润、神经浸润、病理学脾静脉浸润、影像学脾静脉浸润者PFS和OS均显著缩短(均P<0.05)。多因素分析证实,non-IPMN相关腺瘤、pT3期、pN1-2期及术后辅助化疗是PFS和OS的独立危险因素;此外,肿瘤较大和影像学脾静脉浸润同时也是PFS的独立预后因素。结论:应当就如何检测和报告胰体尾癌手术标本的脾血管状态,形成一个统一的规范。 | Feng Yin Mohammed Saad Jingmei Lin Christopher R.Jackson Bing Ren Cynthia Lawson Dipti M.Karamchandani Belen Quereda Bernabeu Wei Jiang Teena Dhir Richard Zheng Christopher W.Schultz Dongwei Zhang Courtney L.Thomas Xuchen Zhang Jinping Lai Michael Schild Xuefeng Zhang Hao Xie Xiuli Liu | 2021 | Gastroenterology Report2021，9，2： | 0 |
| 13 | 卡培他滨联合固定剂量的多西紫杉醇化疗复治非小细胞肺癌的Ⅰ期临床试验(英文)显示文摘Objective:Capecitabine combined with docetaxel have demonstrated antitumor synergy for non-small cell lung cancer (NSCLC). Due to absence of phase I trial in China, we conducted this study to define the maximum-tolerated dose (MTD) of capecitabine with fixed docetaxel for Chinese patients with previously treated NSCLC. Methods:Previously treated patients with NSCLC were entered into this study. Escalating doses of capecitabine with fixed docetaxel were administered in a modified Fibonacci sequence. The initial doses were capecitabine 625 mg/m2, bid, on days d5-d18, and docetaxel 30 mg/m2 on days 1 and 8, respectively. The regimen was repeated every 21 days. If no dose-limiting toxicity (DLT) was observed, the next dose level was applied. The procedures were repeated until DLT appeared. The MTD was declared to be one dose level below the level at which DLT appeared. Results: Eighteen patients received 67 cycles at capecitabine of level I (1250 mg/m2, divided into 625 mg/m2, bid) and level II (1500 mg/m2, 750 mg/m2, bid). The most common toxicities were neutropenia, hand and feet syndrome, fatigue and nausea. Eight DLTs occurred in 5 patients in the whole group, including 1 DLT in dose level I and 7 DLTs in dose level 2. Since 4 of 6 patients in level II experienced DLTs, we declared thus level I was MTD. Conclusion: MTD of our phase I trial was capecitabine of 1250 mg/m2/d combined with docetaxel of 30 mg/m2/wk. This combination regimen was well tolerated for previously treated patients with NSCLC. The efficacy of this schedule is currently being further evaluated in a prospective phase II trial. | Qiang Lin Yue'e Liu Chuilin Chang Na Wang Jingmei Fu Xiaocang Ren Xueji Chen Jing Hu Yansheng Tian Zhijun Guo Yannan Zhao | 2012 | The Chinese-German Journal of Clinical Oncology2012，11，1： | 0 |
| 14 | 接受术后化疗的炎性肠病相关结直肠癌患者的复发率与生存率:一项比较研究显示文摘背景与目的:炎性肠病(IBD)患者具有一定结直肠癌发生风险。研究显示,IBD相关结直肠癌与非IBD相关结直肠癌在肿瘤发生机制和组织形态学上存在差异,提示其肿瘤行为和治疗反应也可能有所不同。我们旨在比较接受术后化疗IBD相关与非IBD相关的结直肠癌患者肿瘤复发及生存率的差异。方法:检索Cleve?land临床中心结直肠癌数据库,筛选出1994-2010年间的65例IBD相关结直肠癌且接受了术后辅助化疗的患者,排除21例临床资料不完整者。按照年龄、手术目的、肿瘤部位、肿瘤病理分级、AJCC分期和T分期,对IBD相关和非IBD相关的结直肠癌患者进行1:4的病例匹配分组。分别采用竞争风险模型和Cox回归模型来评估IBD对无病生存和总体生存的影响。结果:44例IBD相关和176例非IBD相关的结直肠癌患者完成匹配。在IBD组患者中,29例(66%)为溃疡性结肠炎,14例(19%)为克罗恩病,1例(2%)诊断为不确定型肠炎。IBD平均诊断年龄为(28.1±14.5)岁,IBD诊断至结直肠癌治疗的平均间期为(21.5±12.6)年。10例(23%)IBD组患者出现了肿瘤复发,而非IBD组则有34例(19%)复发(P=0.074)。IBD组与非IBD组患者无瘤生存率(HR=0.60;95%CI:0.35~1.05;P=0.074)和总体生存率(HR=0.87;95%CI:0.54~1.4;P=0.58)的差异均无统计学意义。结论:接受术后化疗的IBD相关结直肠癌患者,其复发率与生存率与非IBD相关结直肠癌患者相当。有必要行进一步的前瞻性研究来证实这些发现,以指导治疗决策。 | Mohannad Dugum Jingmei Lin Rocio Lopez Bassam Estfan Elena Manilich Luca Stocchi Bo Shen Xiuli Liu | 2017 | Gastroenterology Report2017，5，1： | 0 |
| 15 | The Role of Sleep Deprivation in Arrhythmias显示文摘Sleep is essential to the normal psychological and physiological activities of the human body.Increasing evidence indicates that sleep deprivation is associated with the occurrence,development,and poor treatment effects of various arrhythmias.Sleep deprivation affects not only the peripheral nervous system but also the central nervous system,which regulates the occurrence of arrhythmias.In addition,sleep deprivation is associated with apoptotic pathways,mitochondrial energy metabolism disorders,and immune system dysfunction.Although studies increasingly suggest that pathological sleep patterns are associated with various atrial and ventricular arrhythmias,further research is needed to identify specific mechanisms and recommend therapeutic interventions.This review summarizes the findings of sleep deprivation in animal experiments and clinical studies,current challenges,and future research directions in the field of arrhythmias. | Wenlong Wang Hongpeng Yin Ge Sun Junpei Zhang Jingmei Sun Nadine Mbabazi Lina Zou Bin Li Pengqi Lin Quanwei Pei Xin Wang Penghe Wang Xuanrui Ji Xiufen Qu Dechun Yin | 2022 | Cardiovascular Innovations and Applications2022，7，3： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员